As of Jul 22
| +0.10 / +3.36%|
The 6 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 5.50, with a high estimate of 10.00 and a low estimate of 2.00. The median estimate represents a +78.57% increase from the last price of 3.08.
The current consensus among 8 polled investment analysts is to Buy stock in BioCryst Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.